MediciNova CFO Resigns; CEO Iwaki Takes Over as Acting Finance Chief
MNOV is trading near its 52-week low of $1.22 (15% above the low).
Summary
MediciNova's CFO resigned November 10 and CEO Yuichi Iwaki was named acting principal financial and accounting officer the next day, disclosed alongside a Q3 net loss of $2.84 million and $29.3 million of cash with runway stated through at least March 2028.
Key Events · Executive and Board Changes · MNOV
-
CFO Resigns, CEO Takes Dual Role
Jason Kruger resigned as CFO on November 10, 2026, and the board named President/CEO Yuichi Iwaki acting principal financial and principal accounting officer on November 11, 2026. The filing states the resignation was not due to any disagreement.
-
Q3 Loss Narrows to $2.84 Million
Net loss was $2.84 million ($0.06 per share) versus $3.05 million a year earlier; nine-month loss fell to $7.74 million from $9.20 million as R&D dropped to $3.54 million from $5.61 million on lower MN-166 study spending.
-
Cash Runway Stated Through March 2028
Cash and equivalents were $29.3 million at September 30, 2026, with working capital of $26.8 million; management says this funds operations at least through March 2028. Operating cash burn was $7.8 million for the nine months.
-
September ATM Sales at $3.22-$3.60
The company sold 2,011,422 shares under the Lucid equity distribution agreement for $6.5 million gross ($0.3 million issuance costs), lifting shares outstanding to 51,232,668 from 49,221,246 at year-end 2025.
Analysis · MNOV · Life Sciences
MediciNova loses its CFO and principal accounting officer with no permanent replacement named, leaving the CEO to sign the financials in both roles. That is a governance gap at a company that just raised money through an at-the-market program and is burning roughly $7.8 million of cash every nine months. The quarter itself was steady: net loss narrowed to $2.84 million from $3.05 million, R&D fell on lower MN-166 spending, and $29.3 million of cash plus $26.8 million of working capital is stated to fund operations at least through March 2028, so this is not a liquidity crisis. The September share sales at $3.22-$3.60 are well above today's $1.40 price, meaning the stock has fallen sharply since that raise and the remaining $50 million Lucid shelf is now a much more dilutive tool if drawn.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNOV was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $1.22 to $3.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.